In this study, we want to see if a new type of medicine for lung cancer treatment is better than the usual treatments. We are curious if this new medicine could improve things for people with lung cancer. This will help us understand if the new medicine will treat people better or faster.

Have you been diagnosed with breast cancer and completed your surgery? Has your doctor recommended hormonal therapy to help prevent your cancer from returning? You may be able to participate in a research study of a new drug called Camizestrant. Please reach out to the research team if you are interested and we will provide information regarding the next steps.

Do you have Stage II or III Breast cancer? If you have enough tissue from your breast cancer diagnosis to send for Mammaprint genomic testing, you may be able to take part in this research study. In this study, we want to learn more about adding an immunotherapy drug, durvalumab, to your chemotherapy treatment. The Mammaprint testing is conducted at no cost to you and the cost of durvalumab is covered.

Do you have intermediate risk prostate cancer and don't want to undergo surgery? You may be able to participate in a research study comparing therapy based on genetic testing.

Do you have Non-Small Cell Lung Cancer? Have you previously been treated with Osimertinib? If so, you may be eligible for a trial comparing osimertinib in combination with other medications to treat your lung cancer. Please reach out if you're interested!

Are you a premenopausal woman with hormone-positive breast cancer? If so, you may be able to participate in a study to learn if adding chemotherapy to the usual treatment improves survival and decreases the chances of cancer coming back.

Do you have stage III colon cancer? Have you already completed surgery? If so, you may qualify for a study that uses a blood test called ctDNA to determine your treatment and to monitor for recurrence.

This is a study for people with early-stage inoperable lung cancer. We want to find out if adding a drug called atezolizumab to stereotactic body radiation therapy (SBRT) is more effective than SBRT alone for this type of cancer.

Do you have triple negative breast cancer? Have you had surgery following chemotherapy? You may be able to participate in a study to find out if stopping pembrolizumab infusions after surgery is just as effective at reducing your risk of cancer recurrence.

Do you have metastatic or recurrent lung cancer? Have you already been treated with chemotherapy or immunotherapy? If so, you may qualify for the LungMap protocol, which will help us identify clinical trials you may be eligible for.